Immuneering ($IMRX) Stock Hub: 43 MAPKeeper Sites, September Events and the Phase 3 Test

03 The Phase 2a dataset: impressive overall survival, modest response rate and an interpretation that must remain disciplined

Results were reported using an April 24, 2026 data cut-off. Median follow-up in the expanded cohort was 11.6 months, while the original 34-patient cohort had 17.0 months of median follow-up and also showed 17.3 months median OS. That consistency is supportive, although the confidence intervals remain wide and survival estimates can move as follow-up matures.

Source: Q2 10-Q.

04 MAPKeeper 301 is the decisive asset test—and its design is built around the endpoint that matters most

MAPKeeper 301 (NCT07562152) is a global, randomized, open-label Phase 3 study in previously untreated metastatic pancreatic ductal adenocarcinoma. The first patient was dosed in June 2026. By the Q2 update, Immuneering said patients were being dosed and more than 30 study locations had been posted.

ClinicalTrials.gov, updated September 4 and checked September 6, lists 510 estimated participants, an actual June 5, 2026 start and 43 recruiting locations: 38 in the United States and five in Australia. Estimated primary completion remains June 2028 and study completion February 2029. The increase from 38 locations in the prior August snapshot is an operational update, not a patient-enrollment count. June 2028 is also RASolute 303’s estimated primary-completion month, but neither registry date establishes when public results will be announced. MAPKeeper 301; RASolute 303.

What success needs to look like

The cleanest outcome would be a statistically persuasive and clinically meaningful OS improvement, supported by PFS and a tolerability or quality-of-life profile that makes the regimen practical. A marginal OS result, a benefit driven by one geography or subgroup, or a safety burden that offsets efficacy would complicate the regulatory and commercial interpretation.

What investors can monitor before topline

Trial-site activation, geographic expansion, enrollment commentary, discontinuation patterns, protocol amendments and changes to the estimated completion date can all provide operational information. None of these substitutes for final randomized efficacy results, but they help distinguish an on-track pivotal program from one accumulating execution friction.

Source: Q2 10-Q · MAPKeeper registry.

05 Pipeline: one lead molecule, several shots on goal and limited diversification today

The pipeline adds optionality, but current valuation remains dominated by pancreatic cancer. The NSCLC study can create an earlier clinical bridge in late 2027, while envometinib is not an active internal value driver unless a partner commits capital and development resources.

Source: Q2 10-Q.

06 Q2 2026 financial position: enough cash for the guided pivotal timeline, with spending now moving higher

June 30 liquidity comprises $41.325M cash and equivalents, $108.576M current marketable securities and $32.773M non-current marketable securities, totaling $182.674M. This equals about $2.824 per July 31 basic share. September 4 basic equity value of $311.841M less that liquidity equals $129.168M; the calculation excludes $3.634M lease liabilities, options, warrants, future spending and financing, and is not a full enterprise-value or risk-adjusted valuation. 10-Q.

The cash-only decline of $87.320M in H1 should not be called operating burn: $52.591M was net investing cash use, mainly purchases of securities net of maturities. Operating activities used $34.935M and financing provided $0.205M from option exercises and the employee share-purchase plan. The filing reports Q2 total operating expense of $19.000M, including $13.997M R&D, $4.996M G&A and $0.007M intangible amortization; Q2 net loss was $17.270M after other income. No product revenue is reported. Source: 10-Q.

Source: Q2 10-Q.

07 Capital structure and dilution: the company is funded, but the fully diluted share count is meaningfully larger

Immuneering had 64.697 million basic shares outstanding at the end of July. The Q2 filing also disclosed approximately 10.965 million stock options and 2.848 million purchase warrants. The warrants carry a $5.50 exercise price and expire in September 2030; none had been exercised as of June 30.

Warrant overhang

If the stock trades sustainably above $5.50, exercise could add up to roughly 2.85 million shares and approximately $15.7 million of gross cash. That is useful capital, but it would dilute existing holders.

ATM capacity

The 2025 ATM showed approximately $98.7 million of remaining gross sales capacity at June 30. No shares were sold under it during H1 2026. The capacity is an option for management, not proof that an offering is imminent.

Option pool

Options are excluded from diluted EPS while the company reports losses, but they still matter to ownership economics. Exercise prices and vesting determine the actual dilution path.

2025 financing anchor

The September 2025 public offering sold 18.96 million shares at $9.23 and raised $164.1 million net; Sanofi’s Aventis subsidiary separately bought 2.71 million shares at the same price. Today’s price sits materially below that financing level, but the financing price is not a valuation floor.

The exact June 30 option count is 10,964,703, with a $4.12 weighted-average exercise price; 6,390,539 were vested and exercisable at a $4.26 weighted average. Purchase warrants total 2,848,096. These are separate instruments from the 64,697,402 outstanding Class A shares. Adding all awards mechanically is not a treasury-stock-method diluted-share calculation and ignores vesting, exercise proceeds and potential forfeitures. Source: 10-Q.

Source: Q2 10-Q.

08 Management and governance: founder-led science with a new finance chief for the pivotal stage

Co-founder and CEO Ben Zeskind, Ph.D., remains central to the company’s scientific narrative and beneficially owned approximately 6.8% of shares as of the April 2026 proxy calculation, including exercisable options and family-trust holdings. Founder alignment is a positive signal, but it also concentrates corporate identity and credibility around one management team and one platform thesis.

Andrew Gengos joined as chief financial officer in July 2026 after serving as CFO and head of corporate development at Terns Pharmaceuticals. Immuneering presented the appointment as an expansion of financial strategy, capital allocation, investor relations and business-development capability. That skill set is relevant as the company manages a global Phase 3, future financing options and potential partnership discussions.

Source: Q2 10-Q.

09 Ownership, analysts and market structure: sophisticated sponsors, thin liquidity and targets that should not be mistaken for evidence

Large disclosed holders

The April proxy listed FMR-affiliated entities at 13.6%, HBM Healthcare Investments at 5.6%, CEO Ben Zeskind at 6.8%, and all current directors and executive officers as a group at 14.9% on a beneficial-ownership basis. BlackRock filed a Schedule 13G in July 2026. Percentages can change with trading and later filings.

Strategic signal from Sanofi

Aventis, a Sanofi subsidiary, purchased 2.71 million shares at $9.23 in September 2025. The agreement provided Sanofi with notice and participation rights around certain strategic processes. This is strategic interest, not a licensing agreement, takeover commitment or validation of Phase 3 success.

Sell-side view

Public aggregators showed bullish ratings and a broad target range of roughly $12–$30 around the research cut-off. Aggregated averages differed by provider and several visible targets predated the Q2 report. Targets are analyst opinions built on probability assumptions, not objective values.

Trading profile

At the September 4 close the market-data provider reports about 1.02M average daily shares traded and 25.93% of float sold short, approximately 14.43M shares. Reported short interest has a lag and is not a real-time position count. This combination can amplify price reactions; it does not by itself predict a squeeze or the clinical outcome. The prior August borrow-status observation is historical and no current stock-loan availability is certified. Finviz.

Retail sentiment

The recurring bullish retail argument centers on the 17.3-month survival headline, cash runway, Sanofi ownership and the gap between the current price and analyst targets. The recurring bearish argument is equally clear: the data are single-arm, the stock has already experienced severe financing-driven dilution, and the definitive readout is distant. Social-media sentiment is not clinical evidence and should be treated as a volatility input only.

BlackRock’s July 28 Schedule 13G reports its June 30 position: 4,356,235 shares beneficially owned, 6.7% of the class, with sole voting power over 4,314,766 and sole dispositive power over 4,356,235. It is an ordinary-course ownership disclosure, not a takeover proposal or evidence that all those shares were bought on the filing date. The holding may overlap institutional aggregates and must not be added to them. BlackRock 13G.

Source: Q2 10-Q.

10 Competitive landscape: atebimetinib must improve survival while remaining practical in a moving first-line market

First-line metastatic pancreatic cancer is no longer a one-regimen market. Standard options include gemcitabine/nab-paclitaxel, FOLFIRINOX or modified FOLFIRINOX, and liposomal irinotecan-based NALIRIFOX for suitable patients. Physicians choose among regimens using performance status, comorbidities, toxicity, access and clinical judgment.

Immuneering’s strategic opportunity is not simply to beat an old historical median. MAPKeeper 301 must show that adding atebimetinib to a modified GnP backbone improves outcomes against a contemporaneous control while preserving enough quality of life to justify another daily agent. Meanwhile, direct RAS inhibitors, pan-RAS/multi-RAS programs, immunotherapy combinations, stromal approaches and other targeted regimens continue to develop.

On August 26, 2026 the FDA approved daraxonrasib (RASONQUE, Revolution Medicines), an inhibitor of the RAS GTPase family, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. Approval rests on RASolute 302 (NCT06625320), a randomized open-label Phase 3 in 500 previously treated patients: median overall survival of 13.2 months against 6.7 months for investigator’s choice chemotherapy, a hazard ratio of 0.40 (95% CI 0.30 to 0.53); median progression-free survival of 7.2 months against 3.6, hazard ratio 0.49 (95% CI 0.38 to 0.64); and an objective response rate of 30% against 11%. The agency cleared the application roughly 6.5 months ahead of its goal date, under the Commissioner’s National Priority Voucher (CNPV) pilot programme and Real-Time Oncology Review, with Project Orbis review shared with Health Canada. The recommended dose is 300 mg orally once daily.

The label covers patients who have already had a systemic line and patients who cannot take multiagent chemotherapy at all, whereas MAPKeeper enrolls untreated, ECOG 0–1 patients suitable for the protocol’s GnP regimen. This distinguishes eligibility populations; it does not prove there is no competitive or enrollment effect. Two consequences still reach $IMRX. The first is what happens after progression: an effective second-line option changes the treatment a first-line patient receives next, and overall survival measured from first-line randomization carries whatever follows in both arms. The second is that the same molecule is already being tested in the first-line setting Immuneering is targeting. RASolute 303 (NCT07491445) is a global three-arm Phase 3 randomizing 900 first-line metastatic pancreatic adenocarcinoma patients to daraxonrasib alone, daraxonrasib plus gemcitabine and nab-paclitaxel, or gemcitabine and nab-paclitaxel; it started on March 9, 2026, carries co-primary endpoints of progression-free and overall survival, and lists a primary completion date of June 2028. A third study, RASolute 304 (NCT07252232), is randomizing 500 resected patients in the adjuvant setting, with primary completion listed for May 2029.

Immuneering addressed the approval the same day. Chief executive Ben Zeskind called it good news for the subset of pancreatic cancer patients who have received at least one prior systemic therapy or cannot take multiagent therapy, and said the priority for the field now moves to first line, where MAPKeeper 301 is enrolling. The release itself, not the quotation, puts the trial at more than 35 locations listed on ClinicalTrials.gov; the registry showed 38 sites in the August 27 snapshot and 43 in the September 4 update. It restates the Phase 2a results, including the only grade 3 or higher treatment-related events above 10% of patients, anemia at 16% and neutropenia at 18%, both attributed to the chemotherapy backbone. It does not name the approved product or its sponsor.

Best competitive feature

A codon-agnostic downstream MEK approach could address a broad PDAC population rather than one narrow KRAS mutation, provided the cyclic pharmacology can overcome the tolerability and resistance limitations of earlier MEK strategies.

Greatest competitive threat

RASolute 303 is testing daraxonrasib in the same first-line population against the same gemcitabine/nab-paclitaxel control, with primary completion estimated in June 2028, near Immuneering’s company-guided mid-2028 MAPKeeper topline window. The RASolute registry estimate is not a confirmed public-results date. A regimen that raises the first-line standard before or alongside that readout could reduce commercial differentiation and force regulators and clinicians to interpret the trial against a landscape that has moved.

Source: Q2 10-Q · FDA · August 26.

11 Timeline: how Immuneering reached the pivotal stage

12 Catalyst map: what can change the stock before the 2028 Phase 3 readout

Earnings reports are operating checkpoints rather than classic revenue events. The most useful quarterly metrics will be cash use, R&D growth, enrollment language, number of active sites, changes to the trial timeline, ATM use and any new partnership economics.

The registry’s primary-completion month is an estimate of data collection, not a confirmed public readout date. NSCLC initiation remains guidance in the latest sources checked, with no later first-patient confirmation found. No date for Q3 earnings has been announced in those sources; a historical November reporting pattern is not a scheduled event. Source: Q2; September schedule.

Source: Q2 10-Q · MAPKeeper registry.

13 Bull case, bear case and the evidence that should change the view

Bull case

• The 17.3-month median OS signal reflects real drug contribution and reproduces in the randomized trial.
• Cyclic MEK inhibition adds survival without the chronic toxicity that limited earlier MEK combinations.
• The $182.7 million balance sheet funds the company through the mid-2028 readout without a distressed financing.
• NSCLC data or a partnership validates the platform before MAPKeeper topline.
• Bulls argue that the current indicative cash-adjusted equity value understates a credible registrational asset.

Bear case

• Cross-trial effects, patient selection or the modified chemotherapy schedule explain much of the Phase 2a result.
• Phase 3 enrollment slips, spending rises faster than planned or the 2028 window moves out.
• A larger trial reveals toxicity, discontinuations or dose-intensity problems not visible in 55 patients.
• Competing regimens improve the first-line standard before approval.
• ATM sales, option exercises and warrants expand the share count before value-defining data.

Observable falsifiers

• A material delay in the MAPKeeper primary-completion date or repeated vague enrollment language.
• A protocol amendment that changes sample size, endpoint hierarchy or population in a way that weakens interpretability.
• Cash runway guidance falling short of the Phase 3 readout without a funded strategic transaction.
• NSCLC initiation moving beyond 2026 or preliminary data moving beyond late 2027.
• New safety disclosures that undermine the tolerability or weight-preservation thesis.

Source: Q2 10-Q.

14 Related Merlintrader coverage

ASCO survival deep dive

ASCO 2026 oncology signals: IMRX, IDYA and NXTC

Biotech research index

Browse all Merlintrader Biotech Stock Hubs

Catalyst calendar

Free FDA, PDUFA and clinical catalyst calendar

Q2 sector context

Biotech Radar: August 5, 2026

The block below is a snapshot of the Stocktwits flow, with its date. These are opinions of retail traders and non-professional investors, not analyst research, and they measure attention and how one-sided positioning has become rather than anything about the business.

15 Follow new Stock Hub updates

Join the English Merlintrader channel for catalyst updates, biotech research and newly refreshed company hubs.

Educational disclaimer: This Stock Hub is independent editorial research for educational and informational purposes only. It is not investment advice, a recommendation, an offer, or a solicitation to buy or sell securities. Biotechnology securities can be extremely volatile and may lose most or all of their value following clinical, regulatory, financing or commercial setbacks. Data and company guidance can change after the research cut-off. Readers should verify current filings and primary sources and make decisions consistent with their own objectives and risk tolerance.